Join Our 15-Minute Ask the Expert Webcast on a Two-Step Strategy for Efficient mAb Purification
Monoclonal antibodies (mAbs) continue to represent a significant portion of the biopharmaceutical pipeline, but their purification remains costly and complex. Standard mAb purification typically requires three chromatography steps: Protein A capture followed by two steps to remove host cell proteins, DNA, charged variants, and aggregates.
Join us as Marian Magdy at Minapharm Pharmaceuticals shares an alternative purification approach using Nuvia™ wPrime 2A Media, a weak AEX-HIC mixed-mode resin, to eliminate one chromatography step following Protein A capture. The result reduces process time, buffer consumption, and media cost while improving overall yield without compromising quality specifications. Because the mixed-mode step can run in flow-through mode, it also adds flexibility in binding capacity, flow rates, and processing times.
Ask the Expert: Optimizing mAb Purification: A Fast, Efficient Two-Step Process Using a Weak AEX-HIC Mixed-Mode Resin
Thursday
8 AM PT | 11 AM ET | 5 PM CEST
Learn a simplified two-step mAb purification strategy using a weak AEX-HIC mixed-mode resin. This approach eliminates an entire chromatography step and enables significant reductions in process time, buffer consumption, and media costs, while increasing product yield.
Key Takeaways
- Lower costs and improve efficiency by eliminating a chromatography step
- Simplify downstream processing with flow-through mixed-mode chromatography
- Increase process flexibility while maintaining product quality
Speaker
Marian Magdy
Protein Purification Manager, R&D Biopharmaceutical Process Development Minapharm Pharmaceuticals
Marian Magdy is a biopharmaceutical professional with nearly 17 years of experience in the industry. A pharmacy graduate from 2001, Marian began her career at the Central Administration of Pharmaceutical Affairs, where she worked until 2008. In 2009, she joined Minapharm as a Downstream Processing Specialist in the R&D Lab, advancing through the ranks to be the Head of the Downstream Department starting 2019. In 2025, she was promoted to be the Manager of the Department. Today, Marian leads the development of the downstream process for several projects including monoclonal antibodies, hormones, and vaccines. She also contributed to the technology transfer and scale-up of several projects to commercial scale.